Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson's Disease?

IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY
Neurologia i neurochirurgia polska Pub Date : 2024-01-01 Epub Date: 2024-07-05 DOI:10.5603/pjnns.99624
Krzysztof Duda, Tomasz Chmiela, Aleksandra Cieśla-Fuławka, Justyna Gawryluk, Joanna Siuda
{"title":"Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson's Disease?","authors":"Krzysztof Duda, Tomasz Chmiela, Aleksandra Cieśla-Fuławka, Justyna Gawryluk, Joanna Siuda","doi":"10.5603/pjnns.99624","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim of study: </strong>We sought to compare MANAGE-PD and 5-2-1 Delphi criteria which are two commonly used and approved screening tools in Parkinson's Disease, in order to highlight their strengths and limitations.</p><p><strong>Clinical rationale for study: </strong>Timely intervention with device-aided therapies is vital as it enables improving motor symptoms, lowering the dosage and side-effects of dopaminergic treatment, and improving patients' and caregivers' quality of life. Various screening tools have been created to help clinicians find the best candidates for device-aided therapies (DAT) for advanced Parkinson's Disease. In this study, we aimed to compare the 5-2-1 Delphi criteria to MANAGE-PD to determine how they could be used specifically to maximise their potential.</p><p><strong>Material and methods: </strong>All of the patients (260) included in this study were DAT-naive, > 18 years of age, diagnosed with Parkinson's Disease, and had been referred to the Department of Neurology for qualification for advanced therapies over a 4-year period (2019-2022). They were subjected to both 5-2-1 Delphi criteria and MANAGE-PD tools and divided into subgroups based on the results of the screening. The data of patients was then statistically analysed.</p><p><strong>Results: </strong>In the study group, 51 patients (19.5%) met all three of the 5-2-1 criteria, and 123 (47.1%) patients were categorised as '3' in MANAGE-PD, meaning that they may benefit from DAT. Finally, at the local centre level, 64 (24.5%) patients were qualified for DAT. 22 (34.4%) patients who were qualified for DAT by a clinician did not meet the 5-2-1 criteria.</p><p><strong>Conclusions: </strong>The 5-2-1 scheme based on the data from this study was characterised by a 92.5% specificity level and 65.1% sensitivity level compared to 69.5% specificity and 98.4% sensitivity level of MANAGE-PD.</p><p><strong>Clinical implications: </strong>We found that MANAGE-PD has a better screening potential of DAT admission than 5-2-1 criteria. While both tools are reliable and valuable in daily practice, our study suggests that some patients may be omitted when using only less complicated tools such as 5-2-1 during the assessment.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia i neurochirurgia polska","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5603/pjnns.99624","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim of study: We sought to compare MANAGE-PD and 5-2-1 Delphi criteria which are two commonly used and approved screening tools in Parkinson's Disease, in order to highlight their strengths and limitations.

Clinical rationale for study: Timely intervention with device-aided therapies is vital as it enables improving motor symptoms, lowering the dosage and side-effects of dopaminergic treatment, and improving patients' and caregivers' quality of life. Various screening tools have been created to help clinicians find the best candidates for device-aided therapies (DAT) for advanced Parkinson's Disease. In this study, we aimed to compare the 5-2-1 Delphi criteria to MANAGE-PD to determine how they could be used specifically to maximise their potential.

Material and methods: All of the patients (260) included in this study were DAT-naive, > 18 years of age, diagnosed with Parkinson's Disease, and had been referred to the Department of Neurology for qualification for advanced therapies over a 4-year period (2019-2022). They were subjected to both 5-2-1 Delphi criteria and MANAGE-PD tools and divided into subgroups based on the results of the screening. The data of patients was then statistically analysed.

Results: In the study group, 51 patients (19.5%) met all three of the 5-2-1 criteria, and 123 (47.1%) patients were categorised as '3' in MANAGE-PD, meaning that they may benefit from DAT. Finally, at the local centre level, 64 (24.5%) patients were qualified for DAT. 22 (34.4%) patients who were qualified for DAT by a clinician did not meet the 5-2-1 criteria.

Conclusions: The 5-2-1 scheme based on the data from this study was characterised by a 92.5% specificity level and 65.1% sensitivity level compared to 69.5% specificity and 98.4% sensitivity level of MANAGE-PD.

Clinical implications: We found that MANAGE-PD has a better screening potential of DAT admission than 5-2-1 criteria. While both tools are reliable and valuable in daily practice, our study suggests that some patients may be omitted when using only less complicated tools such as 5-2-1 during the assessment.

5-2-1 Delphi 标准和 MANAGE-PD 是否是普通神经科医生筛选晚期帕金森病器械辅助疗法资格的有用工具?
研究目的:我们试图比较 MANAGE-PD 和 5-2-1 Delphi 标准这两种在帕金森病中常用且已获批准的筛查工具,以突出它们的优势和局限性:及时干预器械辅助疗法至关重要,因为它可以改善运动症状,降低多巴胺能治疗的剂量和副作用,提高患者和护理人员的生活质量。为了帮助临床医生找到治疗晚期帕金森病的器械辅助疗法(DAT)的最佳候选者,人们开发了各种筛查工具。在这项研究中,我们旨在将 5-2-1 Delphi 标准与 MANAGE-PD 进行比较,以确定如何具体使用这些标准,最大限度地发挥它们的潜力:参与本研究的所有患者(260 人)均无 DAT,年龄大于 18 岁,确诊为帕金森病,并在 4 年内(2019-2022 年)被转诊至神经内科,以获得接受先进疗法的资格。他们同时接受了5-2-1德尔菲标准和MANAGE-PD工具的筛选,并根据筛选结果分为不同的亚组。然后对患者数据进行统计分析:结果:在研究组中,51 名患者(19.5%)符合 5-2-1 标准中的全部三项,123 名患者(47.1%)在 MANAGE-PD 中被归类为 "3",这意味着他们可能从 DAT 中受益。最后,在地方中心层面,64 名(24.5%)患者符合 DAT 条件。22名(34.4%)临床医生认为有资格接受DAT治疗的患者不符合5-2-1标准:结论:基于本研究数据的 5-2-1 方案的特异性水平为 92.5%,灵敏度水平为 65.1%,而 MANAGE-PD 的特异性水平为 69.5%,灵敏度水平为 98.4%:临床意义:我们发现,与5-2-1标准相比,MANAGE-PD具有更好的DAT入院筛查潜力。虽然这两种工具在日常实践中都是可靠和有价值的,但我们的研究表明,如果在评估过程中仅使用 5-2-1 等不太复杂的工具,可能会遗漏一些患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurologia i neurochirurgia polska
Neurologia i neurochirurgia polska 医学-临床神经学
CiteScore
4.20
自引率
27.60%
发文量
128
审稿时长
6-12 weeks
期刊介绍: Polish Journal of Neurology and Neurosurgery is an official journal of the Polish Society of Neurology and the Polish Society of Neurosurgeons, aimed at publishing high quality articles within the field of clinical neurology and neurosurgery, as well as related subspecialties. For more than a century, the journal has been providing its authors and readers with the opportunity to report, discuss, and share the issues important for every-day practice and research advances in the fields related to neurology and neurosurgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信